Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Exclusion Criteria

• •Participants are excluded from the study if any of the following criteria apply:
• •Locally confirmed BRAF V600E mutation
• •Locally confirmed microsatellite instability (MSI)-high or DNA mismatch repair deficiency (dMMR) colorectal cancer
• •Participants with known active symptomatic CNS lesions, including leptomeningeal metastasis, brainstem, meningeal, or spinal cord metastases or compression
• •Clinically significant risk of hemorrhage or fistula
• •Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
• •History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
• •Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
• •Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
• •Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
• •Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis